Stocks To Buy Now

Blog


DGE 4th Next Generation MSL Excellence Summit 2023: Navigating Thought Leader Engagement in the Digital Age

DGE’S 4th Next Generation MSL Excellence Summit will be held on November 13-14, 2023 in Philadelphia, along with a live streaming option. The event revolves around offering lucrative thought leader engagement strategies to MSLs and field executives along with data, tools, and tips to engage with their audiences. As remote meetings have become the preferred means of connection and communication post-covid, strategies need to be reshaped to meet the present challenges.

The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.

Executives must join the event to strengthen technological skills and gain insights into team management. Medical affairs officers, executives & professionals from the health and pharma realm, and regulatory, research and compliance experts can attend the event to explore and learn the evolving skills that help improve team cooperation and relationship management.

Points to discuss at the summit:

  • Determine ways to engage with thought leaders to attain the best performance metrics
  • Find the best strategies for partnerships between MSLs and commercial parties
  • Leverage emotional intelligence to manage KOLs, who prefer to work remotely to gather insights
  • Best ways to achieve success as an MSL
  • Focusing on self-care and the mental health of MSLs
  • Keeping the team engaged in periods of no/little new drug information
  • Designing winning strategies for success during conferences

To know more, please visit https://ibn.fm/jiAlj

From Our Blog

Soligenix Inc. (NASDAQ: SNGX) Pioneering Oral Mucositis Treatment with Novel Therapeutic, Promising Study Results

July 24, 2025

Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed at alleviating this condition, with promising phase 3 data showing substantial improvements in the […]

Rotate your device 90° to view site.